title: Therapeutic efficacy of unilateral subthalamotomy in Parkinson's disease: results in 89 patients followed for up to 36 months.
abstract: BACKGROUND
  Stereotactic thermocoagulative lesions of the subthalamic nucleus (STN) have been shown to induce significant motor improvement in patients with Parkinson's disease (PD).
  
  
  METHODS
  89 patients with PD were treated with unilateral subthalamotomy. 68 patients were available for evaluations after 12 months, 36 at 24 months and 25 at 36 months.
  
  
  RESULTS
  The Unified Parkinson's Disease Rating Scale (UPDRS) motor scores improved significantly contralaterally to the lesion in the "off" and "on" states throughout the follow-up, except for the "on" state at the last evaluation. Axial features and signs ipsilateral to the lesion progressed steadily throughout the study. Levodopa daily doses were significantly reduced by 45%, 36% and 28% at 12, 24 and 36 months post-surgery. 14 patients (15%) developed postoperative hemichorea-ballism which required pallidotomy in eight. These 14 patients had significantly higher dyskinesia scores (levodopa induced) preoperatively than the entire cohort.
  
  
  CONCLUSIONS
  Unilateral subthalamotomy was associated with significant and sustained motor benefit contralateral to the lesion. Further work is needed to ascertain what factors led to severe, persistent chorea-ballism in a subset of patients. Subthalamotomy may be considered an option in circumstances when deep brain stimulation is not viable.
authors.affiliation: Movement Disorders, Functional Neurosurgery and Neurophysiology Units, Centro Internacional de Restauración Neurológica (CIREN), La Habana, Cuba.
authors.forename: L
authors.initials: L
authors.lastname: Alvarez
authors.forename: R
authors.initials: R
authors.lastname: Macias
authors.forename: N
authors.initials: N
authors.lastname: Pavón
authors.forename: G
authors.initials: G
authors.lastname: López
authors.forename: M C
authors.initials: MC
authors.lastname: Rodríguez-Oroz
authors.forename: R
authors.initials: R
authors.lastname: Rodríguez
authors.forename: M
authors.initials: M
authors.lastname: Alvarez
authors.forename: I
authors.initials: I
authors.lastname: Pedroso
authors.forename: J
authors.initials: J
authors.lastname: Teijeiro
authors.forename: R
authors.initials: R
authors.lastname: Fernández
authors.forename: E
authors.initials: E
authors.lastname: Casabona
authors.forename: S
authors.initials: S
authors.lastname: Salazar
authors.forename: C
authors.initials: C
authors.lastname: Maragoto
authors.forename: M
authors.initials: M
authors.lastname: Carballo
authors.forename: I
authors.initials: I
authors.lastname: García
authors.forename: J
authors.initials: J
authors.lastname: Guridi
authors.forename: J L
authors.initials: JL
authors.lastname: Juncos
authors.forename: M R
authors.initials: MR
authors.lastname: DeLong
authors.forename: J A
authors.initials: JA
authors.lastname: Obeso
mesh_terms: D000203:Activities of Daily Living; D000328:Adult; D000368:Aged; D000978:Antiparkinson Agents / Q000627:therapeutic use; D003071:Cognition / Q000502:physiology; D004351:Drug Resistance; D020820:Dyskinesias / Q000453:epidemiology / Q000209:etiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D019635:Neurosurgical Procedures / Q000009:adverse effects; D010300:Parkinson Disease / Q000601:surgery*; D013238:Stereotaxic Techniques; D020531:Subthalamic Nucleus / Q000601:surgery*; D016896:Treatment Outcome
chemical_list: D000978:Antiparkinson Agents; D007980:Levodopa